OLYSIO

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg

Disponible des:

Janssen-Cilag (New Zealand) Ltd

Designació comuna internacional (DCI):

Simeprevir sodium 154.4 mg (equivalent to simeprevir 150.0 mg)

Dosis:

150 mg

formulario farmacéutico:

Capsule

Composición:

Active: Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Gelatin Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Sodium laurilsulfate

tipo de receta:

Prescription

Fabricat per:

Janssen Pharmaceutica NV

indicaciones terapéuticas:

Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, PVC-PE-PVDC blister & Al push-through foil - 7 capsules - 24 months from date of manufacture stored at or below 30°C protect from light - Blister pack, PVC-PE-PVDC blister & Al push-through foil - 28 capsules - 24 months from date of manufacture stored at or below 30°C protect from light

Data d'autorització:

2013-09-02